Research Article| Volume 17, ISSUE 3, P191-196, November 1993

Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women

      This paper is only available as a PDF. To read, Please Download here.


      The transdermal and oral administration of estrogens for one year were compared with respect to the effects on lipid metabolism. Eighty-one postmenopausal women (1.5-3 years after menopause) were randomly divided into three groups. The first two groups received sequential estrogen treatment with either transdermal estradiol (Estraderm TTS, Ciba Geigy; 50 μg/day; 24 women) or 0.625 mg/day conjugated estrogens (Premarin, Wyeth; 20 subjects), respectively. In both groups medroxyprogesterone (10 mg/day per os) was added for 12 days of each cycle. Thirty-five subjects served as control group without therapy. No significant changes in the lipid profile was observed in control subjects after 1 year of follow-up. Serum triglycerides decreased significantly (-10.9 ± 26% S.D.; P < 0.05) in transdermal treated women, whereas it slightly rose in oral estrogen group. Comparable significant decreases in total and low density lipoprotein (LDL) cholesterol (mean range -6.5/-18.0%) were observed in women on estrogen replacement therapy. High density lipoprotein (HDL) cholesterol significantly diminished in transdermal estradiol group, but it rose slightly in the oral estrogen group. Thus the fraction of HDL cholesterol over LDL cholesterol did not change in the transdermal group whereas it significantly rose in subjects treated with oral estrogens. It remains to be established to what extent these differences on lipid metabolism are relevant for the prevention of cardiovascular diseases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gordon T
        • Kannel WB
        • Hjortland MC
        • McNamara PM
        Menopause and coronary heart disease.
        in: The Framingham Study. Ann Intern Med. 89. 1978: 157-161
        • Hjortland MC
        • McNamara PM
        • Kannel WB
        Some atherogenic concomitants of menopause.
        in: The Framingham Study. Am J Epidemiol. 103. 1976: 304-311
        • Matthews KA
        • Meilahn E
        • Kuller LH
        • Kelsey SF
        • Caggiula AW
        • Wing RR
        Menopause and risk factors for coronary heart disease.
        N Engl J Med. 1989; 321: 641-646
        • Bush TL
        • Barrett-Conner E
        • Cowan LD
        • Criqui MH
        • Wallace RB
        • Suchindron CM
        • Tyroler HA
        • Rifkind BM
        Cardiovascular mortality and noncontraceptive use of estrogen in women.
        Circulation. 1987; 75: 1102-1109
        • Barnes RB
        • Roy S
        • Lobo RA
        Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
        Obstet Gynecol. 1985; 66: 217-218
        • Sherwin BB
        • Gelfand MM
        A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clined symptoms and lipoprotein lipids.
        Obstet Gynecol. 1989; 73: 759-766
        • Farish E
        • Fletcher CD
        • Hart DM
        • Christofer Teo HTHT
        • Alazzawi F
        • Howie C
        The effects of conjugated equine oestrogens with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women.
        Acta Endocrinol. 1986; 113: 123-127
        • Basdevant A
        • De Lignieres B
        • Guy-Grand B
        Differential lipemic and hormonal responses to oral and parenteral 17β-estradiol in postmenopausal women.
        Am J Obstet Gynecol. 1983; 147: 77-81
        • Walsh BW
        • Schiff I
        • Rosner B
        • Greenberg L
        • Ravnikar V
        • Sacks FM
        Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
        N Engl J Med. 1991; 325: 1196-1204
        • Jensen Y
        • Riis BJ
        • Strom V
        • Nilas L
        • Christiansen C
        Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women.
        Am J Obstet Gynecol. 1987; 156: 66-71
        • Chetkowski RJ
        • Meldrum DR
        • Steingold KA
        • Randle D
        • Lu JK
        • Eggena P
        • Hershmann JM
        • Alkjaersig NK
        • Fletcher AP
        • Judd HL
        Biologic effects of transdermal estradiol.
        N Engl J Med. 1986; 314: 1615-1620
        • Stanczyk FZ
        • Shoupe D
        • Nunez V
        • Macrias-Gonzales P
        • Vijod MA
        • Lobo RA
        A randomized comparison of nonoral estradiol delivery in postmenopausal women.
        Am J Obstet Gynecol. 1988; 159: 1540-1546
        • Wallace RB
        • Hooier J
        • Barret-Connor E
        • Rifkind BM
        • Hunninghake DB
        • Mackenthun A
        • Heiss G
        Altered plasma lipid and lipoprotein levels associated with oral contraceptives and estrogen use.
        Lancet. 1979; 2: 111-115
        • Fahraeus L
        • Larsson-Cohn U
        Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17β to menopausal women.
        Acta Endocrinol. 1982; 101: 592-596
        • Friedewald WT
        • Levy RI
        • Fredrickson DS
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Oliver MF
        • Boyd GS
        Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels.
        Lancet. 1959; 2: 690-694
        • Henderson BE
        • Paganini-Hill A
        • Ross RK
        Estrogen replacement therapy and protection from acute myocardial infarction.
        Am J Obstet Gynecol. 1988; 159: 312-317
        • McFarland KF
        • Boniface ME
        • Hornung CA
        • et al.
        Risk factors and noncontraceptive estrogen use in women with and without coronary disease.
        Am Heart J. 1989; 117: 1209-1214
        • Sullivan JM
        • Vander Zwaag R
        • Hughes JP
        • et al.
        Estrogen replacement and coronary artery disease.
        Arch Intern Med. 1990; 150: 2557-2562
        • Stampfer MJ
        • Colditz GA
        • Willett WC
        • Manson JE
        • Rosner B
        • Speizer FE
        Postmenopausal estrogen therapy and cardiovascular disease.
        N Engl J Med. 1991; 325: 756-762
        • Gangar KF
        • Vyas S
        • Whitehead M
        • Crook D
        • Meire H
        • Campbell S
        Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause.
        Lancet. 1991; 2: 839-842
        • Lipid Research Clinics Program
        The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
        Jama. 1984; 251: 365-374
        • Tikkanen MJ
        • Nikkila EA
        • Vartiainen E
        Natural oestrogen as an effective treatment for type II hyperlipoproteinaemia in postmenopausal women.
        Lancet. 1978; 2: 490-492
        • Judd H
        Efficacy of transdermal estradiol.
        Am J Obstet Gynecol. 1987; 156: 1326-1331
        • Lufkin EG
        • Wahner HW
        • O'Fallon WM
        • Hodgson SF
        • Katowicz MA
        • Lane AW
        • Judd HL
        • Caplan RH
        • Riggs BL
        Treatment of postmenopausal osteoporosis with transdermal estrogen.
        Ann Intern Med. 1992; 117: 1-9
        • Hirvonen E
        • Lipasti A
        • Malkonen M
        • et al.
        Clinical and lipid metabolic effects of unapposed estrogen and two estrogen-progestagen regimens in post-menopausal women.
        Maturitas. 1987; 9: 69-79
        • Bush T
        • Cowan L
        • Heiss G
        • Chambliss L
        • Wallace R
        Ovarian function and lipid/lipoprotein levels: results from the Lipid Research Clinics Program.
        Am J Epidemiol. 1984; 120: 489
        • Jensen J
        • Nilas L
        • Christiansen C
        Influence of menopause on serum lipids and lipoproteins.
        Maturitas. 1990; 12: 321-331